Help us: Donate
Follow us on:
×

Menu

Back

Month: June 2018

Today we are pleased to announce that UNITY Biotechnology is going into human clinical trials with the first true rejuvenation therapy that directly targets one of the processes of aging: senescent cells. The quiet revolution In our collective imagination, revolutions start with a bang; however, more often than not, real-life technological revolutions start quietly and...
After meeting him at the Astana Global Challenges Summit 2018, we've kindly been granted an interview by Dr. Anthony Atala, M.D., Director of the Wake Forest Institute for Regenerative Medicine and the W. Boyce Professor and Chair of Urology at Wake Forest University. Dr. Atala is one of the most influential names in the field...
Today, we conclude our two-part interview with Dr. Michael Fossel, you can find part one here. Changing tack a bit here, you talk a little bit in your book about programmed human death; we're basically programmed to die through evolution's weird workings and you kind of flesh out what Josh Mitteldorf calls the demographic theory...
Lifespan Extension Advocacy Foundation is hosting a conference in New York to encourage investment in rejuvenation technologies NEW YORK, June. 27, 2018 — Lifespan Extension Advocacy Foundation (LEAF), a non-profit organization that supports scientific research on aging and longevity via its own crowdfunding platform, Lifespan.io, is hosting Ending Age-Related Diseases: Investment Prospects & Advances in...
Today, we have part one of a two-part interview with Dr. Michael Fossel, the driving force behind Telocyte, a new company focused on telomerase therapy for various diseases, and a strong advocate of telomerase therapy to treat human disease over the past three decades. You can find part two of the interview here. I interviewed...
For the June edition of Journal Club, we discussed the recent paper entitled “Changes at the nuclear lamina alter binding of pioneer factor Foxa2 in aged liver“. We had also summarized the research in an article earlier this month. Summary Increasing evidence suggests that regulation of heterochromatin at the nuclear envelope underlies metabolic disease susceptibility and...